CliffBio
biologic

Trazimera

trastuzumab-qyyp

Loss of exclusivity—loss of exclusivity
CompanyPfizer Ireland Pharmaceuticals Unlimited Company

Drug detail

Brand nameTrazimera
Active ingredienttrastuzumab-qyyp
Strength420MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalMarch 2019
Marketing statusRx

More from Pfizer Ireland Pharmaceuticals Unlimited Company

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

Trazimera patent cliff — loss of exclusivity — | CliffBio